Compare CANF & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CANF | SNOA |
|---|---|---|
| Founded | 1994 | 1999 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 6.1M |
| IPO Year | N/A | 2007 |
| Metric | CANF | SNOA |
|---|---|---|
| Price | $4.11 | $3.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $9,750.00 | N/A |
| AVG Volume (30 Days) | ★ 74.6K | 12.9K |
| Earning Date | 03-26-2026 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $560,000.00 | ★ $16,937,000.00 |
| Revenue This Year | $461.72 | $23.00 |
| Revenue Next Year | N/A | $24.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 25.02 |
| 52 Week Low | $3.36 | $1.75 |
| 52 Week High | $46.60 | $6.92 |
| Indicator | CANF | SNOA |
|---|---|---|
| Relative Strength Index (RSI) | 64.56 | 29.76 |
| Support Level | $4.00 | $3.28 |
| Resistance Level | $4.32 | $3.57 |
| Average True Range (ATR) | 0.29 | 0.14 |
| MACD | -0.16 | -0.03 |
| Stochastic Oscillator | 31.61 | 0.00 |
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.